DNA microarray diagnostic market is set to reach $500m by 2010
This article was originally published in Clinica
Executive Summary
So far, only a smattering of clinical diagnostics firms are selling DNA microarray-based assays. But following advancements in the field, clinical DNA microarrays are now on the brink of a boom and are likely to generate a $500m niche market in just two years time, according to Bertrand Jordan, founder and former head of genetics consortium Genopole, and scientific consultant for three microarray companies. Clinica's Claire Thomas caught up with Dr Jordan shortly after the recent Advances in Microarray Technology Conference in Edinburgh, Scotland